Literature DB >> 23118232

Cancer cells induced to express mesenchymal phenotype release exosome-like extracellular vesicles carrying tissue factor.

Delphine Garnier1, Nathalie Magnus, Tae Hoon Lee, Victoria Bentley, Brian Meehan, Chloe Milsom, Laura Montermini, Thomas Kislinger, Janusz Rak.   

Abstract

Aggressive epithelial cancer cells frequently adopt mesenchymal characteristics and exhibit aberrant interactions with their surroundings, including the vasculature. Whether the release/uptake of extracellular vesicles (EVs) plays a role during these processes has not been studied. EVs are heterogeneous membrane structures that originate either at the surface (microparticles), or within (exosomes) activated or transformed cells, and are involved in intercellular trafficking of bioactive molecules. Here, we show that epithelial cancer cells (A431, DLD-1) adopt mesenchymal features (epithelial-to-mesenchymal transition-like state) upon activation of epidermal growth factor receptor (EGFR) coupled with blockade of E-cadherin. This treatment leads to a coordinated loss of EGFR and tissue factor (TF) from the plasma membrane and coincides with a surge in emission of small, exosome-like EVs containing both receptors. TF (but not EGFR) is selectively up-regulated in EVs produced by mesenchymal-like cancer cells and can be transferred to cultured endothelial cells rendering them highly procoagulant. We postulate that epithelial-to-mesenchymal transition-like changes may alter cancer cell interactions with the vascular systems through altered vesiculation and TF shedding.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23118232      PMCID: PMC3527943          DOI: 10.1074/jbc.M112.401760

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

Review 1.  EGF-ERBB signalling: towards the systems level.

Authors:  Ami Citri; Yosef Yarden
Journal:  Nat Rev Mol Cell Biol       Date:  2006-07       Impact factor: 94.444

Review 2.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

3.  Tissue factor-mediated endocytosis, recycling, and degradation of factor VIIa by a clathrin-independent mechanism not requiring the cytoplasmic domain of tissue factor.

Authors:  C B Hansen; C Pyke; L C Petersen; L V Rao
Journal:  Blood       Date:  2001-03-15       Impact factor: 22.113

4.  Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis.

Authors:  Joanne L Yu; Linda May; Vladimir Lhotak; Siranoush Shahrzad; Senji Shirasawa; Jeffrey I Weitz; Brenda L Coomber; Nigel Mackman; Janusz W Rak
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

Review 5.  Thrombophilia in cancer.

Authors:  Anna Falanga
Journal:  Semin Thromb Hemost       Date:  2005-02       Impact factor: 4.180

6.  Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation.

Authors:  Ian Del Conde; Corie N Shrimpton; Perumal Thiagarajan; José A López
Journal:  Blood       Date:  2005-03-01       Impact factor: 22.113

7.  Cellular localization and trafficking of tissue factor.

Authors:  Samir K Mandal; Usha R Pendurthi; L Vijaya Mohan Rao
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

8.  In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease.

Authors:  J Contrino; G Hair; D L Kreutzer; F R Rickles
Journal:  Nat Med       Date:  1996-02       Impact factor: 53.440

9.  Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein.

Authors:  Vladimir Y Bogdanov; Viji Balasubramanian; James Hathcock; Oana Vele; Mark Lieb; Yale Nemerson
Journal:  Nat Med       Date:  2003-03-24       Impact factor: 53.440

10.  E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1).

Authors:  B St Croix; C Sheehan; J W Rak; V A Flørenes; J M Slingerland; R S Kerbel
Journal:  J Cell Biol       Date:  1998-07-27       Impact factor: 10.539

View more
  56 in total

Review 1.  Tumor-derived exosomes in oncogenic reprogramming and cancer progression.

Authors:  Sarmad N Saleem; Asim B Abdel-Mageed
Journal:  Cell Mol Life Sci       Date:  2014-08-26       Impact factor: 9.261

2.  Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles.

Authors:  Nadim Tawil; Rayhaan Bassawon; Brian Meehan; Ali Nehme; Laura Montermini; Tenzin Gayden; Nicolas De Jay; Cristiana Spinelli; Shilpa Chennakrishnaiah; Dongsic Choi; Lata Adnani; Michele Zeinieh; Nada Jabado; Claudia L Kleinman; Michael Witcher; Yasser Riazalhosseini; Nigel S Key; David Schiff; Steven P Grover; Nigel Mackman; Charles P Couturier; Kevin Petrecca; Mario L Suvà; Anoop Patel; Itay Tirosh; Hamed Najafabadi; Janusz Rak
Journal:  Blood Adv       Date:  2021-03-23

3.  Tissue Factor Regulation by miR-520g in Primitive Neuronal Brain Tumor Cells: A Possible Link between Oncomirs and the Vascular Tumor Microenvironment.

Authors:  Esterina D'Asti; Annie Huang; Marcel Kool; Brian Meehan; Jennifer A Chan; Nada Jabado; Andrey Korshunov; Stefan M Pfister; Janusz Rak
Journal:  Am J Pathol       Date:  2015-12-12       Impact factor: 4.307

4.  Inhibition of oncogenic epidermal growth factor receptor kinase triggers release of exosome-like extracellular vesicles and impacts their phosphoprotein and DNA content.

Authors:  Laura Montermini; Brian Meehan; Delphine Garnier; Wan Jin Lee; Tae Hoon Lee; Abhijit Guha; Khalid Al-Nedawi; Janusz Rak
Journal:  J Biol Chem       Date:  2015-08-13       Impact factor: 5.157

Review 5.  Exosomes: a new weapon to treat the central nervous system.

Authors:  Luca Braccioli; Cindy van Velthoven; Cobi J Heijnen
Journal:  Mol Neurobiol       Date:  2013-07-16       Impact factor: 5.590

Review 6.  Tumor-Derived Exosomes and Their Role in Cancer Progression.

Authors:  Theresa L Whiteside
Journal:  Adv Clin Chem       Date:  2016-04-07       Impact factor: 5.394

7.  Comparison of microvesicle tissue factor activity in non-cancer severely ill patients and cancer patients.

Authors:  Yohei Hisada; Charlotte Thålin; Staffan Lundström; Håkan Wallén; Nigel Mackman
Journal:  Thromb Res       Date:  2018-03-07       Impact factor: 3.944

8.  Analysis of the thrombotic and fibrinolytic activities of tumor cell-derived extracellular vesicles.

Authors:  Ludovic Durrieu; Alamelu Bharadwaj; David M Waisman
Journal:  Blood Adv       Date:  2018-05-22

Review 9.  Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review.

Authors:  Asfar S Azmi; Bin Bao; Fazlul H Sarkar
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

Review 10.  Extracellular Vesicles in Brain Tumor Progression.

Authors:  Esterina D'Asti; Shilpa Chennakrishnaiah; Tae Hoon Lee; Janusz Rak
Journal:  Cell Mol Neurobiol       Date:  2016-03-18       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.